Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Combination anti-arrhythmic drug therapy].

B Lüderitz1, W Jung, M Manz

  • 1Medizinische Universitäts-Klinik, Innere Medizin-Kardiologie/Pneumologie, Bonn.

Zeitschrift Fur Kardiologie
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of obstructive sleep apnea on heart rate turbulence.

Basic research in cardiology·2005
Same author

[Postoperative arrhythmias].

Deutsche medizinische Wochenschrift (1946)·2005
Same author

[Atrial fibrillation -- interventional therapy with respect to age].

Deutsche medizinische Wochenschrift (1946)·2005
Same author

Progression of native coronary plaques and in-stent restenosis are associated and predicted by increased pre-procedural C reactive protein.

Heart (British Cardiac Society)·2005
Same author

Atrial fibrillation: profit from cardiac pacing?

Zeitschrift fur Kardiologie·2005
Same author

[Progressive upper lobe consolidation in a 73-year old healthy woman].

Der Internist·2005

Combining antiarrhythmic drugs can improve treatment efficacy in refractory cases. Careful patient selection and close monitoring are crucial due to potential proarrhythmic effects.

Area of Science:

  • Cardiology
  • Clinical Pharmacology

Background:

  • Single-agent antiarrhythmic therapy often proves insufficient and carries risks of dose-dependent side effects.
  • Combination therapy with lower, well-tolerated doses is recommended for refractory arrhythmias.
  • Combining drugs from the same electrophysiologic class is generally discouraged.

Purpose of the Study:

  • To evaluate the efficacy and safety of combined antiarrhythmic drug therapy.
  • To explore specific drug combinations, including beta-blockers with Class I agents and Class III with Class IB agents.
  • To assess the impact of combinations on refractory ventricular tachycardia.

Main Methods:

  • Investigated combinations of beta-adrenoreceptor blockers with Class I antiarrhythmic drugs.
  • Examined combinations of Class III agents (e.g., amiodarone, sotalol) with Class IB agents (e.g., mexiletine, tocainide).

Related Experiment Videos

  • Assessed amiodarone combined with Class IC agents (flecainide, encainide) in amiodarone-refractory patients.

    • Main Results:

    • Combinations like amiodarone/mexiletine and sotalol/mexiletine showed electrophysiological and clinical utility.
    • Amiodarone with Class IC drugs prolonged ventricular tachycardia cycle length but did not prevent induction.
    • Amiodarone and encainide combination demonstrated significant proarrhythmic effects.

    Conclusions:

    • Combination antiarrhythmic therapy can enhance treatment efficacy in selected patients.
    • Specific combinations, such as Class III and Class IB agents, can be beneficial.
    • Close monitoring is essential due to the inherent risk of proarrhythmia with combination therapy.